Currently approved prophylactic HPV vaccines

Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123.

Abstract

Cervarix and Gardasil are two prophylactic HPV vaccines designed primarily for cervical cancer prevention. Cervarix is effective against HPV-16, -18, -31, -33 and -45, the five most common cancer-causing types, including most causes of adenocarcinoma for which we cannot screen adequately. Gardasil is effective against HPV-16, 18 and 31, three common squamous cell cancer-causing types. In addition, Gardasil is effective against HPV-6 and -11, causes of genital warts and respiratory papillomatosis. The most important determinant of vaccine impact to reduce cervical cancer is its duration of efficacy. To date, Cervarix's efficacy is proven for 6.4 years and Gardasil's for 5 years.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / prevention & control*
  • Adenocarcinoma / virology
  • Adolescent
  • Adult
  • Alphapapillomavirus / immunology*
  • Cervical Intraepithelial Neoplasia / prevention & control
  • Cervical Intraepithelial Neoplasia / virology
  • Clinical Trials as Topic
  • Condylomata Acuminata / prevention & control
  • Condylomata Acuminata / virology
  • Drug Approval*
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Humans
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Infections / virology
  • Papillomavirus Vaccines* / administration & dosage
  • Papillomavirus Vaccines* / adverse effects
  • Papillomavirus Vaccines* / immunology
  • Treatment Outcome
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology
  • Young Adult

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines
  • human papillomavirus vaccine, L1 type 16, 18